Sun Yingni, Rong Xianfang, Lu Wenwen, Peng Ying, Li Jiang, Xu Shaofeng, Wang Ling, Wang Xiaoliang
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
J Alzheimers Dis. 2015;45(1):269-82. doi: 10.3233/JAD-142805.
The aim of this study was to investigate potential biomarkers of Alzheimer's disease (AD). Changes in protein expression in brain tissues from AβPP/PS1 transgenic mice were evaluated using two-dimensional gel electrophoresis combined with LC-MS/MS. A total of 23 differentially expressed proteins were successfully identified in brain tissues of which 11 were validated by western blot. Then, the levels of these differentially expressed proteins in serum from AD patients and healthy controls were examined. Of these 11 proteins, levels of 5 changed in the same direction in the serum of AD patients as they did in mouse brain: cathepsin B, VDAC1, and cofilin-2 increased, and Alix and ACAP1 decreased. Alix, cofilin-2, and ACAP1 have not been previously associated with AD. More importantly, the serum levels of Alix, cofilin-2, and ACAP1 were significantly different between AD patients and healthy controls. Furthermore, the expressions of cathepsin B, cofilin-2, VDAC1, and ACAP1 strongly correlated with the Mini-Mental State Examination scores of the AD patients. The results indicate that these proteins are putative biomarkers of AD which may be useful in its diagnosis and in the evaluation of new anti-AD drugs both in pre-clinical and clinical studies.
本研究的目的是调查阿尔茨海默病(AD)的潜在生物标志物。使用二维凝胶电泳结合液相色谱-串联质谱法(LC-MS/MS)评估AβPP/PS1转基因小鼠脑组织中的蛋白质表达变化。在脑组织中成功鉴定出总共23种差异表达蛋白,其中11种通过蛋白质印迹法进行了验证。然后,检测了AD患者和健康对照者血清中这些差异表达蛋白的水平。在这11种蛋白中,AD患者血清中5种蛋白的水平变化方向与小鼠脑中相同:组织蛋白酶B、电压依赖性阴离子通道蛋白1(VDAC1)和丝切蛋白-2增加,而Alix和ARF-GAP1(ACAP1)减少。Alix、丝切蛋白-2和ACAP1以前未与AD相关联。更重要的是,AD患者和健康对照者之间Alix、丝切蛋白-2和ACAP1的血清水平存在显著差异。此外,组织蛋白酶B、丝切蛋白-2、VDAC1和ACAP1的表达与AD患者的简易精神状态检查得分密切相关。结果表明,这些蛋白是AD的假定生物标志物,可能有助于其诊断以及在临床前和临床研究中评估新的抗AD药物。